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Abstract
Background: Progressive Supranuclear Palsy (PSP) is a sporadic and progressive neurodegenerative disease which
belongs to the family of tauopathies and involves both cortical and subcortical structures. No effective therapy is to
date available.
Methods/design: Autologous bone marrow (BM) mesenchymal stem cells (MSC) from patients affected by
different type of parkinsonisms have shown their ability to improve the dopaminergic function in preclinical
and clinical models. It is also possible to isolate and expand MSC from the BM of PSP patients with the same
proliferation rate and immuphenotypic profile as MSC from healthy donors. BM MSC can be efficiently delivered
to the affected brain regions of PSP patients where they can exert their beneficial effects through different
mechanisms including the secretion of neurotrophic factors.
Here we propose a randomized, placebo-controlled, double-blind phase I clinical trial in patients affected by PSP
with MSC delivered via intra-arterial injection.
Discussion: To our knowledge, this is the first clinical trial to be applied in a no-option parkinsonism that aims to
test the safety and to exploit the properties of autologous mesenchymal stem cells in reducing disease progression.
The study has been designed to test the safety of this “first-in-man” approach and to preliminarily explore its efficacy by
excluding the placebo effect.
Trial registration: NCT01824121
Keywords: Progressive supranuclear palsy, Parkinson’s disease, Mesenchymal stem and stromal cells, Advanced therapy
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Background
Progressive supranuclear palsy (PSP) is a rare form of
parkinsonism with a prevalence of about 0.5 cases per
100,000 inhabitants and with an incidence of 5.3 new
cases every 100,000 inhabitants [1,2]. Its etiology is un-
known. From a pathological point of view, the disease
consists in a neurodegenerative process that involves the
basal ganglia, the brainstem, the prefrontal cortex and the
cerebellum, with accumulation of a tau protein - hence
the classification as tauopathy [3]. Onset typically occurs
after 40 years of age. The symptoms include bradykinesia,
proximal and axial rigidity and early postural instability.
The key sign, which gives the disease its name, is the
supranuclear paralysis of vertical gaze, followed by abnor-
malities of horizontal gaze. This sign usually appears three
or four years after the onset of motor symptoms. The
most disabling symptoms, especially in the early phases of
the disease, are stiff, upright posture and abnormal gait
with a very broad base associated with severe postural
instability and frequent falls, especially backwards. The
patient is confined to a wheelchair on average after 5
years of disease. Levodopa response is poor or absent
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[4-6]. Mean survival amounts to 7 years [7]. Early falls,
speech and swallowing problems, diplopia and early
insertion of a percutaneous gastrostomy are predictors
of reduced survival [8].
The differential diagnosis between PSP and the other
parkinsonisms is made according to clinical criteria [9].
Molecular biology studies have shown that the parkinson-
isms share a common pathogenesis, namely the intraneur-
onal accumulation of misfolded proteins that cannot be
removed normally. The misfolding is caused by structural
abnormalities due to genetic mutation and/or exposure to
environmental factors [10]. The syndromes have been
classified according to the kind of misfolded proteins that
accumulate: synucleinopathies, in which the main accu-
mulated protein is alpha-synuclein, and tauopathies, in
which it is protein tau [11]. Unfortunately the greater
understanding of the parkinsonisms in terms of mo-
lecular biology has not resulted in the finding of a cure.
At present all these movement disorders are incurable.
However, symptomatic treatment is available. It consists
mainly in dopaminergic treatment (levodopa and dopa-
mine agonists), which controls symptoms for several
years in Parkinson’s Disease (PD), whereas the response
is generally poor and short-lived in the other syndromes
[12]. Moreover, even in PD it is not effective on the
most disabling symptoms, such as postural instability
and freezing. Also surgical treatment is available. It
consists in the implantation in strategic positions of
electrodes for deep brain stimulation, which corrects
electrical circuit imbalances occurring in circumscribed
parts of the brain in PD patients [13,14]. However, this
treatment is not suitable for the other syndromes, in
which the neurodegenerative process is more extensive
and general conditions deteriorate more rapidly.
Summary of pre-clinical data to support the use of
autologous MSC in PSP patients
Mesenchymal stem cells (MSC) are multipotent cells that
can be isolated from many sources, including bone mar-
row (BM). Besides their in vitro and in vivo potential to
transdifferentiate into several mesodermal lineages, their
therapeutic relevance is mostly due to their immunosup-
pressive and anti-inflammatory properties [15]. Other
paracrine actions of MSC have been claimed to act in
several animal models of diseases and also in preliminary
clinical trials [16-18]. Indeed, the real MSC trans-
differentiation capacity seems to have limited clinical
relevance, with the exception of bone differentiation
that is currently exploited in different orthopaedic trials
[19]. The main expected pharmacological effect of BM
MSC on dopaminergic neurons that support their use
in PSP is the potential to regulate cell differentiation and
function by reducing oxidative stress and apoptosis.
Regarding this potential mechanism of action, there
are several experimental evidences of the neurotrophic
effect of MSC that result in the reduction of tissue damage
and neuronal loss. The brain derived neurotrophic factor
(BDNF) and the glial derived neurotrophic factor (GDNF)
have been recently identified as the putative mediators
of this effect. BDNF is a protein belonging to the neu-
rotrophine family that promotes neuronal growth, dif-
ferentiation and survival in different areas of central
and peripheral nervous system. The molecular pathway
that mediates the BDNF effects on cell survival is well
known and documented [20]. Briefly, the homodimeric
BDNF induces the dimerization of the thyrosin-kinase
receptor B, the binding of ATP to the intracellular ATP-
binding loop, and in turn the stimulation of the kinase
activity. The autophosphorylation of the tyrosine triplet
in the kinase domain is a prerequisite for further phos-
phorylation steps (via Src homology 2/collagen-related
protein and PIK3and MAPK pathways) that finally medi-
ate the effects of the neurotrophin on neuronal survival,
differentiation, and gene expression as well as acute effects
on synaptic transmission [21].
Also the molecular basis of GDNF mechanism of action
is well know and consists essentially in its interaction with
the GDNF-family receptor-alpha (GFRa1), on the activa-
tion of the Ret tyrosine-kynase [22] and on the PLCγ, PI3/
Akt and MEK-ERK1/2 pathway [23]. Nevertheless, it is
also known that the GDNF- GFRa1 complex can work
independently from Ret activation by activating the Src
family and consequently the c-AMP-response element
binding protein (CREB) [24,25]. All these mechanisms
have a central role in regulating the survival of dopa-
minergic neurons [26]. The precise balancing of these
signals results in the definition of neuronal cell fate in
response to different noxa.
In order to establish the role of the hypothesized mech-
anism of action, the ability to synthesize and secrete BDNF
and GDNF by MSC from PSP patients and healthy donors
has been evaluated, by real–time PCR and by ELISA. The
results are shown in Figure 1 and they demonstrate that
MSC from PSP are able to produce as main neurotrophine
as MSC from healthy donors. For that reason, BDNF and
GDNF secretion from MSC will be measured during the
clinical protocol as potency assay. The use of cells instead
of the simple administration of synthetic proteins has
several advantages. First of all endogenously produced
neurotrophines are in principle fully bio-available since
MSC could be able to vehicle directly the neurotrophines
to the damaged tissue. In this regard, it has been already
demonstrated that MSC are able to overcome the
brain–blood barrier [27,28]. MSC may also act by re-
leasing extracellular vesicles, including exosomes and
microvescicles, which transport lipids and different mRNA
functional transcripts, microRNA, long non-coding RNA
and occasionally genomic DNA and therefore they could
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be able to transfer genetic information that may induce
transient or persistent changes in the recipient cells [29].
Methods/design
The current trial is a prospective, randomized, sham-
controlled, phase I clinical study to evaluate the safety and
efficacy of autologous mesenchymal stem cell intra-arterial
infusion in patients with PSP. The protocol has been autho-
rized by the local Ethics Committee of Fondazione IRCCS
Ca’ Granda Ospedale Maggiore Policlinico of Milano, Italy,
and by the National Competent Authority for phase I cell
therapy protocol at Istituto Superiore di Sanità.
Figure 1 Pre-clinical data. Bone marrow mesenchymal stem cells from patients affected by progressive supranuclear palsy have the typical
spindle-shaped morphology (A), are positive for mesenchymal-specific antigens to an extended flow-cytometric analysis (B) and express BDNF
and GDNF as those from healthy subjects, as demonstrated by real time PCR (C) and ELISA (D). BM MSC: bone marrow mesenchymal stem cells;
PSP: Progressive Supranuclear Palsy; HS: healthy subjects. The results of flow cytometric analysis, Elisa and PCR are expressed as mean (±SD).
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Primary and secondary objectives
The primary objective is to assess the safety of autologous
MSC therapy in patients with PSP in a “first-in-man”
context.
The secondary objective is to assess the efficacy of
autologous MSC therapy in patients with PSP in terms
of stabilization or improvements in motor function,
neuropsychological parameters and neuroimaging findings.
Exploratory objectives
Exploratory objectives will help to identify the mecha-
nisms underlying the effect of MSC on neurodegeneration.
Whit this aim, the ability of MSC to in vitro rescue 6-
OHDA damaged neural cell lines and to synthesize and
secrete neurotrophines will be measured to determine if
these factors are related to the clinical response.
Study design
All patients over the age of 40 years with diagnosis of
“probable progressive supranuclear palsy - Richardson’s
disease subtype” according to current diagnostic criteria
[4; 9] are eligible (Table 1).
The first 5 patients are treated in an open phase with
autologous MSC therapy with the same procedures as
for the randomized phase.
After these first 5 patients have been followed-up for a
minimum of 2 months from the cellular infusion, the ISS
Data Safety Monitoring Board will review the safety data
prior to open the accrual of the subsequent randomized
controlled phase.
In the randomized phase the patients undergo to:
– immediate autologous MSC therapy followed by
delayed sham or
– immediate sham followed by delayed autologous
MSC therapy.
The delay amounts to 6 months and all patients will
be followed-up for at least 12 months after MSC therapy,
so the total duration of the study is 18 months. The study
design is shown in Figure 2.
Bone marrow collection and MSC isolation
Bone marrow is aseptically drawn by qualified medical
staff at the Bone Marrow Transplantation Centre - Fonda-
zione IRCCS Ca’ Granda Ospedale Maggiore Policlinico
Milano according to standard procedures. The maximum
quantity of bone marrow to be collected is 30 ml. The
isolation of BM MSC is performed under Good Manu-
facturig Practices (GMP) conditions as requested by
European Regulations for cell-based advanced therapy
medicinal product (ATMPs) in the “Cell Factory” La-
boratory of Fondazione IRCCS Ca’ Granda Ospedale
Maggiore Policlinico Milano. The “Cell Factory” was
the first public Italian hospital-based facility to receive
authorization for the production of ATMPs (Agenzia
Italiana del Farmaco – AIFA – authorization n°120/2007
and subsequent confirmations, the last in 2013). The
procedures for BM MSC aseptic production and quality
control have been developed by the authors. Briefly,
unprocessed BM is directly seeded in alpha Modified
Eagle Medium supplemented with 10% FBS at the con-
centration of 50,000 total nucleated cells (TNC)/cm2 in
Cell Stack Chamber system (Corning, Lowel, MA). After
72 hours, non-adherent cells are removed by washing
with PBS (Macopharma, Mouvaux, France) with complete
medium change. Medium changes are also performed
twice a week. On day 14 (±3) MSC at P0 are detached
using 25 mL/layer of TrypLE- Select (Gibco-Life Tech-
nologies, Carlsbad, CA, USA) and re-seeded in the same
culture conditions at the concentration of 4000 MSCs/
cm2. The culture is stopped at 28 days (±3) of culture
(passage 2) and the cells are re-suspended in a solution
containing normal saline solution with human serum
albumin (Kedrion, Castelvecchio Pascoli, Lucca, Italy) 10%
(vol:vol) and DMSO (Bioniche Lifesciences, Inc., Belleville,
ON, Canada) 10% (vol:vol). The cell product is cryopre-
served using a controlled-rate freezer (Nicool Plus, Air
Liquide) programmed to freeze at −1 C/ min and is stored
in the vapor phase of liquid nitrogen in bags (CryoMACS
Miltenyi, Teterow, Germany). The day of the infusion, the
cells are thawed at 37°C and resuspended (1:2) in normal
saline solution with human serum albumin (Kedrion) 10%
(vol:vol) and ACD-A 12% (Fresenius Kabi, Bad Homburg,
Germany). Finally, volume is adjusted to 200 mL with
normal saline solution alone.
Administration of MSCs
Patients undergo neuroleptoanalgesia and are monitored
by an anesthesiologist. MSCs are administered by intra-
arterial route, as already described [28], with modifications
according to local equipment and local standards: with Sel-
dinger technique, catheterization is carried out via the right
common femoral artery (or the left one in the event of dif-
ficulty in achieving arterial access) using a 6 F Ultimum EV
(St Jude Medical, Minnetonka, MN, USA) introducer and a
5 F Hinck or Simmons (Terumo Europe NV, Leuven,
Belgium) diagnostic catheter. An angiographic study of the
cervical and intracranial arteries is performed, with the sup-
port of a 0.035 inch, 150 cm long hydrophil guide (Terumo
Europe NV, leuven, Belgium). Subsequently, with or with-
out an exchange maneuver, using a 260 cm Starter ex-
change (Boston Scientific, Natick, MA, USA), a Mach
190 cm catheter guide (Boston Scientific, Natick, MA,
USA) is used, after intravenous administration of a bolus of
heparin sodium (3,000 to 5,000 IU according to body mass)
to reduce the risk of thromboembolism. The catheter
guide will be positioned in the widest vertebral artery.
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Subsequently, the main catheter is placed in both internal
carotid arteries and a microcatheter is moved forward up
to the widest vertebral artery.
The MSC are then injected into the various districts
with an automated peristaltic pump, via the microcatheter.
Should any ulcerated atherosclerotic plaques be found
at carotid bifurcations, therapy is injected proximally
to the lesion. Once therapy administration has been
completed, MRI of the brain is performed with two
sequences, FLAIR and DWI. Patients are closely moni-
tored for 3 hours after the procedure and then moved
to the Neurosurgery Unit, where they spend the next
24 hours. Provided that the procedure was uneventful,
they are discharged the day after the cell injection.
Patients undergoing the sham procedure are monitored
in the same way.
Table 1 Inclusion and exclusion criteria
Inclusion criteria -Diagnosis of ’probable Progressive Supranuclear Palsy - Richardson’s disease subtype’
according to current diagnostic criteria [4; 9], including akinetic-rigid syndrome;
-Age at onset ≥ 40 years;
-Disease duration 12 months to 8 years;
-Supranuclear ophthalmoplegia;
-Postural instability or falls within 3 years from disease onset;
-Positive MRI for PSP criteria (Quattrone et al., [30]);
-Stable pharmacological treatment for at least 90 days;
-Lack of response to chronic levodopa (at least 12-month treatment);
-Able to stand in upright posture without assistance for at least 30 seconds;
-Written informed consent (including video taping).
Exclusion criteria -Idiopathic Parkinson’s disease;
-Cerebellar ataxia;
-Symptomatic autonomic dysfunction;
-Evidence of any other neurological disease that could explain signs;
-History of repeated strokes with stepwise progression of parkinsonian features;
-History of major stroke;
-Any history of severe or repeated head injur;
-A history of encephalitis;
-A history of neuroleptic use for a prolonged period of time or within the past 6 months;
-Street-drug related parkinsonism;
-Significant other neurological disease on CT-scan/MRI;
-Oculogyric crises;-major signs of corticobasal degeneration;
-Signs of Lewy body disease;
-Other life-threatening disease likely to interfere with the main outcome measure;
-Any clinically significant laboratory abnormality, with the exception of cholesterol, triglycerides and glucose;
-Renal failure (serum creatinine >300 mM/L);
-Transaminase elevation > twice upper limit of normal;
-Any concomitant disorder associated with bone marrow function impairment;
-Any concomitant disorder that requires chronic treatment with immunosuppressors,
anti-inflammatory agents, and/or growth factors;
-Dementia (MMSE < 24 according to Folstein 1975 or defined according to DSM-IV TR criteria);
-Any other disorder that could interfere with the evaluation of treatment or that could make
intra-arterial infusion inadvisable;
-Any other features that, according to the investigator, could reduce adherence to protocol procedures or prevent
rapid access in case of emergency;
-Women of child-bearing age;
-Participation in another clinical trial with experimental treatment in the last 30 days;
-Brain MRI evidence of severe vascular abnormalities, space-occupying lesions or normal pressure hydrocephalus.
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Motor status assessment
The patients undergo neurological examinations designed
to assess motor function using the following scales:
Unified Parkinson’s Disease Rating Scale (MDS-
UPDRS) total and motor score [31];
Hoehn and Yahr staging [32];
PSP rating scale [33] to specifically rate PSP severity;
SEADL (Schwab England Activities of Daily Living);
CGI (Clinical Global Impression for disease severity) [34];
If the patient is taking dopaminergic therapy, the
neurological assessment is performed twice: in OFF upon
wakening and in ‘ON’ after taking therapy in the morning
by the same neurologist.
After patient’s consent, the entire neurological examin-
ation is video-recorded so that the evaluation can be
performed again by assessors blind to allocation.
Multifactorial movement analysis
Patients perform four tasks:
(1.) upright standing;
(2.) starting to walk;
(3.) linear free gait (with and without a cognitive task);
(4.) gait along a curvilinear trajectory.
Tests are carried out in the order listed above as already
described with minor modifications [35], if possible given
the clinical status of the patient, before and after MSC
therapy. Each test requires 4–8 walks, at intervals of about
5–10 minutes, on a platform about 10 meters long at a
comfortable speed. The cognitive task consists in a calcu-
lation (counting backwards, starting from 100 and sub-
tracting 7 at a time). The patients are not corrected or
stopped if they make mistakes in calculating. The curvilin-
ear test consists in straight walking for 2 meters towards
the center of the platform and then a curvilinear trajectory
with an angle of 90° for another 2 meters. Data are col-
lected with a SMART optoelectronic movement analysis
system (BTS SpA, Italy) equipped with: (i) optoelectronic
system (six cameras with 60 Hz acquisition frequency) to
establish the position of 29 reflecting markers applied
onto the skin of the patients at anatomical landmarks (ii)
three dynamometric platforms (KISLER, GmbH, Winther-
tur, Switzerland) with 960 Hz acquisition frequency to
record ground reaction forces; (iii) TELEMG telemetric
electromyograph (BTS SpA) and a FreeEMG wireless
electromyography to measure muscular activity of tibialis
anterior and soleus bilaterally.
Figure 2 Study design. A) Pilot phase; B) Randomized study.
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Neuropsychological assessment
The following tests are performed:
– Mini Mental State Examination (MMSE) [36]
– Neuropsychological measures: verbal
comprehension; perceptual organization, immediate
memory (story, design, word list learning), delayed
memory (story, design, word list recall), word list
recognition, language (confrontation naming,
category fluency, letter fluency, auditory
comprehension), attention/concentration,
visuospatial ability (block design), processing speed,
executive functioning (cognitive flexibility).
Quality of life
Quality of life is assessed by asking the patients to fill-in
the PDQ-8 questionnaire [37] at baseline, and 6 and 12
months after MSC therapy.
Neuroimaging
All patients perform a longitudinal neuroimaging assess-
ment at baseline and 6, 12 and 18 months after MSC ther-
apy, using striatal dopamine transporter Single Photon
Emission Computed Tomography (SPECT) and Positron
Emission Tomography (PET) using a tropanic tracer
labeled with Iodine-123 (FP-CIT) for SPECT imaging
and Iodine-124 (Beta-CIT) for PET/TC imaging. SPECT
studies are carried after intravenous administration of
110-140 MBq of 123I-FP-CIT (Datscan®, GE-Health,
Amersham, UK) performed 30–40 minutes after thyroid
blockade (10–15 mg of Lugol solution per os) in all sub-
jects. 18 F-fluorodeoxyglucose positron emission tomography
(FDG-PET/TC) is performed 4–6 hours and 20–24 hours
after intravenous injection of 18–30 MBq of 124I- Beta-CIT.
All patients undergo 18 F-fluoro-2-deoxy-D-glucose posi-
tron emission tomography scanning (FDG-PET) at rest,
after intravenous injection of 285 to 296 MBq.
Safety
Toxicity is evaluated following the National Cancer Insti-
tute Common Toxicity Criteria Manual (CTCAE v 4.0)
[38]. At screening demographic information, medical
history and specific history of PSP (age at onset, signs and
symptoms, previous investigations, with particular refer-
ence to neuroimages, treatment) are collected. Patients are
monitored closely after the MSC/sham procedure for 3
hours at the day-hospital of the Diagnostic and Interven-
tional Neuroradiology Unit and subsequently at the ward
of the Neurosurgery Unit until discharge the next day.
A general medical examination and routine laboratory
tests are performed at every visit, plus any further in-
vestigations that are deemed necessary according to the
findings of the general medical examination.
Statistics
General considerations
As noted above, the safety of cellular therapy administra-
tion in the first five patients will be reviewed by the Data
Safety Monitoring Board. These reviews will be shared
with our institutional IRB. If the treatment appears safe, as
determined by the Data Safety Monitoring Board with in-
stitutional IRB agreement, the protocol may be reopened
to treat a total of 20 patients.
For statistical analysis of efficacy endpoints, descriptive
statistics are computed for variables of interest (mean and
SD for continuous variables and frequencies for categorical
variables). Test results are summarized over time using ap-
propriate graphical or tabular formats. The non parametric
pair wise Wilcoxon rank sum test will be used to investigate
each variable within subject and between the same subject
at different follow-up (e.g. pre- vs. post-MSC, pre- vs. post-
sham, etc.). The use of a non-parametric test has been
considered the most appropriate since the distribution
of the variable is not known and the number of obser-
vations is relatively small. For each time point, the test
will be performed with 20 paired values (the values be-
fore and after MSC therapy in the 10 subjects allocated
to immediate treatment plus the 10 subjects allocated
to the delayed treatment).
P-values < 0,05 will be considered statistically significant.
Additional summary statistics are also considered as
appropriate to the data.
Safety data
A descriptive analysis of all AEs and ADRs will be
provided.
The tabulations of laboratory data will be provided
together with the normal ranges of the laboratory, high-
lighting any values that are out of range.
Motor function
A descriptive analysis of the course of the main end-
points will be provided:
– change in total, ADL, motor and part IV UPDRS score;
– change in Hoehn & Yahr stage;
– change in PSP rating scale (cognitive disturbances,
bulbar functions, limb function, ocular motor
function);
– change in SEADL;
– CGI score.
Multifactorial movement analysis
The data related to each of the four tests will be normalized
and the mean of the values related to each variable re-
corded during the 8 walks will be calculated. The data
before and after MSC therapy will be compared using
Wilcoxon’s signed rank test for matched pairs, considering
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the patients before and after treatment as a pair (the re-
sults at each follow-up visit will be assessed separately).
Moreover, the results obtained in PSP patients will be
compared with those obtained in the group of age-
matched healthy volunteers using the non-parametric
Mann–Whitney U Test.
Neuropsychological assessments
A descriptive analysis of the course of the main endpoints
(change in each of the test scores vs baseline will be
provided).
Neuroimaging assessment
The main neuroimaging parameter will be:
– specific striatal uptake of the labeled ligand for
SPECT analysis; this parameter measures the striatal
density of dopamine transporters
– normalized labeled ligand subcortical and cortical
uptake for PET analysis; this parameter measures
normalized regional cerebral flow/glucose
metabolism in the gray matter of the brain.
The analysis will be performed using ANOVA to assess
changes in cerebral volume by SPM software. Significance
will be set at p<0.01.
Translational endopoints
In vitro model of tissue damage and repair
In our laboratory we set up an in vitro assay to assess
the effect of MSC on neural cell damage and repair.
Human neuroblastoma cell line SK-N-BE, cultured in
appropriate medium, is damaged using 6-OHDA. After
24 hours, the cells are washed and MSC from PSP pa-
tients and, in parallel, from healthy subjects are added
in no-contact co-culture using Transwell® Permeable
supports. At different time points (0, 48, 72 and 144 hours)
the viability of SK-N-BE cells is checked by quantification
using 3-(4,5-dimethylthiazole-2yI)-2,5-diphenyltetrazolium
bromide (MTT assay). In addition, at all the above defined
time points, the supernatant are collected and stored
at −80 C for the ELISA quantification.
Neurotrophine produced by MSC
In order to investigate the role of neurotrophines secreted
by autologous MSC from PSP patients as mediators of
their neuro-rescue potential, the production of multiple
neurotrophic factors will be evaluated throw a multiplex
sandwich ELISA (matrix metalloproteinase 2/3/9/13 -
MMP 2/3/9/13; BDNF; GDNF; neurotrophin 3 - NT-3;
basic nerve growth factor - BNGF, ciliary neuronotrophic
factor - CNTF) on MSC supernatants and a quantitative
RT-PCR analysis (for BDNF and GDNF) on MSC RNA
extract.
Innovation
The proposed first-in-man study has several innovative
characteristics. First, we demonstrated that it is possible
to produce an advanced therapy medicinal product,
manufactured in compliance to GMP rules from the
bone marrow of patients affected by PSP and that this
product has the same safety profile as that produced
from healthy donors. Second, we translated the concept
of using MSC as a cell-based delivery system not only
for neurotrophic factors, but also for different types of
nucleic-acid-containing vesicles, able to transiently or
permanently transfer genetic information to the surround-
ing cells. Moreover, the presented study aims to document
the putative effect of cell therapy by combining clinical
evaluation and multifactorial movement analysis. We have
therefore established a multidisciplinary platform to study
the effect of cell-based advanced therapy that can be
applied not only to PSP patients, but also to other neu-
rodegenerative disorders (e.g. MSA, PD, etc.).
Discussion
Cell-based advanced therapy is a novel and extremely
promising option to cure otherwise untreatable neurode-
generative diseases but there are still several bottle necks
that slow the progression and the widening of clinical
trials in this context. Mainly, despite the overall positive
results reported in several small studies in PD and MSA,
there is a lot of uncertainness regarding the real capacity
of MSC to reach the brain, the selectivity of their targets
and their real mechanism of action. Moreover, in PD as
well as in atypical parkinsonisms no validated biomarker
is available to follow-up the neuroprotective effect of
putative disease-modifyng treatments. So, why are we
performing this trial? First: there are several positive
results in other no-option parkinsonisms as well as in
PD that deserve to be confirmed also in other pathologic
context like PSP. Therefore, even thought the primary
objective of this protocol is to demonstrate the safety of
autologous MSC intra-arterial administration in subjects
affected by PSP, we have designed a sham-controlled
study, with the aim to document efficacy as well. Second,
we would like to indirectly get information on the putative
neuroprotective mechanism of action of MSC in PSP by
comparing the in vitro results of the proposed potency
assay and the clinical outcome. The biological hypothesis
underlying the rationale of the proposed protocol is that
MSC can reduce the neural cell loss in PSP by reducing
cell apoptosis and the detrimental consequence of oxida-
tive stress on neural cell homeostasis. Whit this premises,
it should be clear to the reader that, the objective of
making neurons from stem cells is out of the scope of
our approach. Nevertheless, the story of replacing lost
neurons in parkinsonisms by transplantation has been
pursued for years. At first tissue was transplanted. In
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the 1980s autologous adrenal gland medullary tissue
was transplanted first in animals and then in humans.
Significant clinical improvements were achieved, but
common and even serious postoperative complications
induced clinicians to abandon this option [39-44]. In the
1990s non-autologous fetal neuron transplantation was
attempted. Clinical benefits were modest and confined to
younger patients (<60 years), and complications occurred
i.e. the appearance of postoperative dyskinesias that in
a few cases were severe and refractory to treatment. PET
investigations suggested that these cases were due to an
imbalance in the dopaminergic circuits induced by the
transplanted cells [45,46]. Recent in vivo brain imaging
findings in two patients, who had exhibited major motor
recovery after transplantation, suggested that the cause of
the dyskinesias was a serotonergic hyperinnervation [47].
An alternative explanation is that an immune response
was responsible for both the appearance of dyskinesias
and the modest extent of the therapeutic benefits [48].
Furthermore, the autopsies of subjects who had received
fetal mesencephalic dopaminergic neurons disclosed
the presence of Lewy bodies, raising the possibility of
host-to-graft disease propagation. Thus, the prospects
for dopaminergic fetal neuron transplantation in PD do
not appear to be promising [49]. Autologous stem cell
transplantation has been proposed for the most common
form of parkinsonism, PD [50]. This proposal overcomes
the ethical reservations related to the use of fetal cells or
embryonic stem cells, and removes the risk of transplant
rejection. Even thought the ability of different bone-
marrow derived stem cells to migrate into the brain
and to differentiate into cells bearing neural markers
have been postulated even in vivo [51-53], the proven
evidence of the so-called neural plasticity have never been
demonstrated. Indeed, in the last years the attention of
most investigators has been addressed to study the poten-
tial of BM mesenchymal stem cells to positively influence
neural cell survival and to reduce cell apoptosis [54-56].
MSC have proved to be able to produce different kinds of
growth factors that increase neuronal survival, to possess
immunoregulatory properties able to influence inflamma-
tory conditions and to migrate to damaged tissue areas
where they might contribute to counteract neurodegener-
ation. What is more, they can be easily harvested from the
bone marrow of the patients, easily expanded on a large
scale for autotransplantation, and administered to patients
via various routes [57]. MSCs have been isolated from
PD patients and they do not differ from those of healthy
subjects in terms of phenotype, morphology and ability to
differentiate [58]. Furthermore, it has been demonstrated
that MSCs exert neuroprotective effects on dopaminergic
neurons both in vitro and in animal models of PD (rats
given the toxin MG-132 or 6-OHDA), mediated by
anti-inflammatory activity and the secretion of growth
factors [59-62]. Of particular interest is the fact that in
the rats given MG-132, a proteasome inhibitor, MSCs
also reduced the accumulation of polyubiquinated pro-
teins, a finding that suggests that they also contribute
to correct proteasome dysfunction, which is believed to
play an important role in the pathogenesis of PD [60].
Autologous MSC therapy would therefore appear to
be an important candidate for the development of a
parkinsonism-modifying therapeutic strategy.
To our knowledge, four pilot clinical trials have been
published on the use of autologous stem cell transplant-
ation in patients with primary parkinsonism. Two studies
[63,64] have been conducted in patients with multiple
system atrophy (MSA). The first one was an open-label,
controlled trial designed to assess the feasibility and
safety of MSC therapy by intra-arterial and intravenous
route in which eleven MSA patients were infused MSC
therapy through the internal carotid artery and the
proximal portion of the vertebral artery once and by
intravenous route thereafter once a month for three
months. Treated patients were compared to 18 untreated
control MSA patients. Follow-up was continued up to one
year after the beginning of treatment and consisted in
neurological examinations using the unified MSA rating
scale scores (UMSARS). In addition, 5 treated patients
and 10 untreated patients underwent brain metabolism
imaging using PET and 18 F-fluoro-deoxyglucose (FDG).
After 12 months mean total UMSARS score was similar
to the score at baseline in the treated group (functional
stabilization), whereas it had worsened in the control
group (p = 0.002). Moreover, treated patients showed
increased brain metabolism by means of FDG-PET, while
the untreated group had decreased uptake. The most
significant adverse events reported was the occurrence
in 7 patients of small spotty lesions on MR images that
were considered to be asymptomatic microemboli, a
frequent complication of catheterization techniques. The
same group recently published the results of a second
protocol, in which thirty-three patients with probable
MSA-C were randomly assigned to receive MSC via intra-
arterial and intravenous routes or placebo. The primary
outcome was change in the total UMSARS scores from
baseline throughout a one-year follow-up period between
groups. In this study, the MSC group had a smaller in-
crease in total and part II UMSARS scores compared
with the placebo group. Cerebral glucose metabolism
and gray matter density were more extensively decreased
in the cerebellum and the cerebral cortical areas, along
with greater deterioration of frontal cognition in the
placebo group compared with the MSC group. No serious
adverse events directly related to MSC treatment were
recorded. However, intra-arterial infusion resulted again in
small ischemic lesions on MR. In another open-label clin-
ical trial [65], autologous BM MSCs were transplanted
Giordano et al. Journal of Translational Medicine 2014, 12:14 Page 9 of 13
http://www.translational-medicine.com/content/12/1/14
into a sublateral ventricular zone of the brain by stereo-
taxic surgery in 7 male patients aged 22 to 62 years with
advanced PD. The diagnosis was based on the presence of
the classical symptoms and a good response to levodopa.
The patients were followed up for 10 to 36 months. Three
of the patients experienced motor improvement compared
to baseline; the mean extent of improvement in UPDRS
score was 22.9% in OFF and 38% in ON. Two of the pa-
tients were able to reduce the dosage of their antiparkin-
son medications. No serious adverse events occurred. MRI
imaging did not disclose any significant changes. The last
study [28] was an open-label clinical trial conducted by
interventional radiologists, who subjected 53 patients
with a diagnosis of PD made according to UK Brain
Bank criteria to intraarterial autologous implantation of
mononuclear cells from bone marrow. The cells were
introduced by intraarterial catheterization, infusing the
cells into the posterior part of the circle of Willis, from
which the perforating arteries that irrigate the basal
nucleus and the substantia nigra originate. Four patients
received a second implant. None of the patients had
major complications. They experienced major signifi-
cant changes in median disease severity scores: UPDRS,
Hoehn & Yahr, Schwab & England and Northwestern
University Disability Scale (NUDS). In eight patients
follow-up MR spectroscopy revealed mean improvements
in n-acetylaspartate/creatine ratio. These studies demon-
strated the feasibility of autologous cell transplantation in
patients with parkinsonism, but they did not demonstrate
efficacy, because their design did not ensure objective
measurements. Also, clinical improvement could have
been influenced by the beliefs of patients and investigators
alike as they were open-label studies. Neuroimaging
changes could not be easily dismissed, but they were
available only in a few patients and did not focus on
the kind of damage that is seen in parkinsonism. A
search in the WHO worldwide clinical trial database on
August 1, 2013 disclosed 390 studies assessing MSC
therapy. Out of these only other three studies are on-
going in patients with Parkinson. To our knowledge
this is the first time that autologous MSC therapy is
given to PSP patients.
In this kind of cell therapy protocols, a crucial question
is how to fix the optimal cell dose to be administered to
the patients and which is the best administration route,
considering together the safety aspects and the efficacy
objectives. When the protocol was conceived, the dose to
be given was established based on several considerations.
In particular, although there were data showing that MSCs
in PD patients do not differ from those of healthy subjects
in terms of phenotype, morphology and ability to dif-
ferentiate into other cells [58], a preliminary study was
conducted in PSP patients, to check the bone marrow
function and MSC yield and to establish how many
cells could be realistically produced for administration.
The elements that have been used for the definition of
the cell dose were the quaantity of MSCs that was
obtained from maximum 30 mL of bone marrow and
the cell dose that was given in the three protocols that
were previously performed with MSC in parkinsonisms
(1-2×106/kg). Thus, the cell dose was fixed at 1.5 ±
0.5 ×106/kg. Regarding the route of administration,
several possibilities were considered. Systemically injected
MSC undergo intra-pulmonary cell trapping [66] and
therefore only a limited amount of cells might home to
the brain. Stereotaxic-guided intra-striatal implantation
was excluded in consideration of the pathologic character-
istics of PSP that has a much wider distribution compared
to classic Parkinson disease and for safety concerns, since
there are several evidences that intra-striatal cell adminis-
tration may cause harm and reduce efficacy by evoking
a local cellular immune response [67]. Therefore, we
decided to use superselective arterial catheterization to
implant stem cells throw the arteries that feed the brain
regions affected by PSP to release in situ the highest
concentration of MSC. This technique has been used in
the three out of four previous clinical trial in parkin-
sonisms, with no major adverse events out of the report
of asymptomatic microembolism. To minimize this
risk, several precautions have been taken in our proto-
col during the preparation of the cell product such as
dilution of the cells to less than 1 × 10E6 cells/mL and the
addition of an anticoagulant (ACD-A) to the solution in
which the cells are re-suspended before infusion.
In this study a “pure” control group treated with placebo
solution administered by the same route in a double-
blinded manner is missing since this option was consid-
ered not acceptable by the ethical point of view by the
investigators, given the potential harm of a cerebral artery
catheterization procedure that is not justified by a poten-
tial benefit. Nevertheless, the patients enrolled in the
control harm receive a simulated arterial catheterization
and administration procedure and the neurologist and the
neuro-radiologist who perform the follow-up evaluation
are blinded. In this way, we exclude the placebo effect with
the best precision.
In conclusions, the presented protocol is the first attempt
to understand if MSC can be safely administered and can
exert a beneficial effect in PSP patients. We believe that
the results of this trial will help to improve the knowledge
around the neuroprotective properties of MSC that might
be exploited in other several neurodegenerative disorders.
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